Therapeutic Goods (Charges) Amendment Bill 2026
UnknownSummary
The Therapeutic Goods Administration currently charges fees to companies that want to register medicines, medical devices, and other health products in Australia. This amendment changes how those fees work — it updates the charges that companies pay when they submit products for approval, renewal, or other regulatory processes under the Therapeutic Goods Act 1989. The changes matter because they affect the cost of bringing new medicines and devices to Australian patients; higher fees might slow down approvals or increase medicine prices, while lower fees could speed up access but reduce funding for safety checks.
Bill Progress
Senate
First Reading
Second Reading
Committee of the Whole
Third Reading
House of Representatives
First Reading
Second Reading
Consideration in Detail
Third Reading
Royal Assent
Royal Assent